-
公开(公告)号：EP2109613A2
公开(公告)日：2009-10-21
申请号：EP07759283.0
申请日：2007-03-23
IPC分类号： C07D487/04 , A61K31/4985 , A61P25/20
摘要： The present invention provides crystalline Eszopiclone malate form II, crystalline Eszopiclone form V, processes from preparing the crystalline Eszopiclone malate form II or V, pharmaceutical compositions comprising the crystalline Eszopiclone malate form II or V and methods of treating insomnia comprising administering the crystalline Eszopiclone malate form II or V.
-
2.发明公开(S)-N,N-DIMETHYL-3-(1-NAPHTHALENYLOXY)-3-(2-THIENYL) PROPANAMINE-DI-P-TOLUOYL-L-TARTARATE AND METHODS OF PREPARATION THEREOF 审中-公开（S）-N，N-二甲基-3-（1-萘甲酰氧基）-3-（2-噻吩基）丙酰胺 - 二 - 对 - 戊醇-L-十八烷酸钠在HERSTELLUNGSVERFAHREN
公开(公告)号：EP1858874A1
公开(公告)日：2007-11-28
申请号：EP06738315.8
申请日：2006-03-14
发明人： INI, Santiago , KOLTAI, Tamas , ABRAMOV, Mili
IPC分类号： C07D333/22 , A61K31/38 , A61P13/00 , A61P25/24 , A61P29/00
CPC分类号： C07D333/16 , A61K31/38 , C07D333/20
摘要： The invention provides (S)-N,N-Dimethyl-3-(l-naphthalenyloxy)-3-(2- thienyl) propanamine-Di-p-toluoyl-L-tartarate (DNT-L-pTTA), which can be used as an intermediate in the preparation of duloxetine hydrochloride, processes for the preparation of DNT-L-pTTA, a crystalline form of DNT-L-pTTA, and processes for the preparation of duloxetine hydrochloride form DNT-L-pTTA (Formulae (I) and (II)).
-
公开(公告)号：EP1853571A1
公开(公告)日：2007-11-14
申请号：EP06735977.8
申请日：2006-02-24
发明人： KOLTAI, Tamas , NIDAM, Tamar , BRAUDE, Viviana , FINE, Serguei
IPC分类号： C07D263/20
CPC分类号： C07D263/20 , A61K31/5377 , C07D413/10 , C07D413/14
摘要： The present invention relates to novel crystalline forms of the linezolid intermediate S-N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine referred to herein as Form A, Form B, and Form C.
摘要翻译： 本发明涉及本文称为A型，B型和C型的利奈唑烷中间体S-N-（4-吗啉基-3-氟苯基）-2-氧代-5-恶唑烷基 - 甲基胺的新型结晶形式。
-
公开(公告)号：EP1511739A1
公开(公告)日：2005-03-09
申请号：EP04757623.6
申请日：2004-03-17
发明人： RUKHMAN, Igor , FLYAKS, Evgeni , KOLTAI, Tamas , ARONHIME, Judith
IPC分类号： C07D257/04 , A61K31/41
CPC分类号： C07D257/04
摘要： Provided are crystalline and amorphous form of valsartan, and processes for their preparation.
-
公开(公告)号：EP2101570A1
公开(公告)日：2009-09-23
申请号：EP07867741.6
申请日：2007-12-13
发明人： FRENKEL, Anton , KOLTAI, Tamas
IPC分类号： A01N33/02 , A61K31/135
CPC分类号： C07C211/42 , C07C2602/08 , C07H13/08
摘要： The subject invention provides rasagiline tannate, compositions and a process for manufacture thereof.
摘要翻译： 本发明提供了雷沙吉兰丹宁酸盐，组合物及其制备方法。
-
公开(公告)号：EP1954691A2
公开(公告)日：2008-08-13
申请号：EP07796071.4
申请日：2007-06-12
发明人： KOLTAI, Tamas , HEDVATI, Lilach
IPC分类号： C07D401/12 , A61K31/4184 , A61P1/04
CPC分类号： C07D401/12
摘要： Provided are amorphous and crystalline forms of pantoprazole magnesium salt and processes for their preparation.
-
公开(公告)号：EP1844025A1
公开(公告)日：2007-10-17
申请号：EP06718294.9
申请日：2006-01-11
发明人： KOLTAI, Tamas , MALACHI, Omer , SASSON, Nisim , GOLD, Amir
IPC分类号： C07D257/04
CPC分类号： C07D257/04
摘要： The present invention provides a process for the preparation of amorphous valsartan.
-
公开(公告)号：EP1817280A1
公开(公告)日：2007-08-15
申请号：EP05853079.1
申请日：2005-12-05
发明人： ARONHIME, Judith , KOLTAI, Tamas , SAMBURSKI, Guy , LEHRMAN, Ori , IZSAK, Reuven
IPC分类号： C07D205/08
CPC分类号： C07D205/08
摘要： Provided are processes for preparing crystalline forms of ezetimibe, such as ezetimibe Form A or Form B, for example, by precipitating ezetimibe from selected solvents. Alternatively, some forms may be transformed into different forms at elevated temperatures or under various humidity conditions, or by micronization. Also provided are micronized ezetimibe Form A, micronized ezetimibe Form B, and ezetimibe having a plate morphology. Pharmaceutical compositions containing these forms are particularly useful in reducing cholesterol in patients in need thereof.
-
公开(公告)号：EP1812428A2
公开(公告)日：2007-08-01
申请号：EP05852062.8
申请日：2005-11-21
发明人： IZSAK, Reuven , LERMAN, Ori , KOLTAI, Tamas , ARONHIME, Judith , PINCHASOV, Michael , EISEN-NEVO, Hagit
IPC分类号： C07D413/04 , A61K31/422 , A61P25/06
CPC分类号： C07D413/06
摘要： The invention encompasses novel crystalline forms of zolmitriptan herein defined as Form B, D, C, E, F, G, H, I, J, K, M, N, O, P, Q, R, S, or Amorphous and to methods of making thereof. The invention also encompasses methods of making zolmitriptan crystalline Form A.
-
公开(公告)号：EP1713795A2
公开(公告)日：2006-10-25
申请号：EP05713277.1
申请日：2005-02-11
IPC分类号： C07D403/10
CPC分类号： C07D403/10
摘要： Provided are candesartan cilexetil forms and methods of their preparation. Also provided are pharmaceutical compositions prepared by combining at least one pharmaceutically-acceptable excipient with at least one candesartan cilexetil form of the invention.
-
-
-
-
-
-
-
-
-
搜索结果
36 条记录 (耗时 0.017 秒)
